potassium disorders
Hyperkalaemia (UKKA 2023): mild 5.5–5.9, moderate 6.0–6.4, severe ≥6.5 mmol/L. ECG for K⁺ ≥6.0. ECG changes → IV calcium (gluconate 30 mL 10% over 10 min). Shift with insulin 10 units + glucose 25 g ± salbutamol. Remove with SZC (not SPS), diuretics or dialysis. Check K⁺ at 1, 2, 4, 6 and 24 h. Long term: treat the K⁺ (diet, diuretic, binder) and keep the RASi going. Hypokalaemia: replace Mg²⁺, then sort renal vs GI loss by urine K⁺, BP and acid–base.
- Hyperkalaemia with ECG changes (peaked T, wide QRS, loss of P, sine wave, brady/VT) → IV calcium now; a normal ECG doesn’t exclude danger
- Severe hypokalaemia (<2.5) or any hypokalaemia with arrhythmia, digoxin or DKA → IV replacement, cardiac monitoring
- Haemodialysis patient with K⁺ ≥6.5 → urgent dialysis; still give IV calcium if the ECG is toxic
severe hyperkalaemia admission bundle (UKKA 2023)
- 12-lead ECG for K⁺ ≥6.0; continuous monitoring if ≥6.5, ECG changes, or 6.0–6.4 and unwell
- VBG K⁺ while awaiting the lab; suspect pseudohyperkalaemia → paired lithium-heparin + serum samples, prompt analysis
- ECG changes → Ca gluconate 10% 30 mL IV over 10 min (CaCl₂ 10% 10 mL over 5 min if peri-arrest); repeat if changes persist
- K⁺ ≥6.5 → insulin 10 units soluble + glucose 25 g IV; moderate (6.0–6.4) → consider
- pre-treatment glucose <7.0 → 10% glucose 50 mL/h for 5 h afterwards
- glucose at 0, 30, 60, 90, 120, 180, 240, 300, 360 min
- salbutamol 10–20 mg nebulised as an adjunct (never alone)
- SZC 10 g TDS for up to 72 h (≥6.5; consider at 6.0–6.4) or patiromer 8.4 g daily
- stop K⁺-raising drugs (RASi, MRA, K⁺-sparing diuretics, trimethoprim, NSAIDs, supplements)
- K⁺ at 1, 2, 4, 6 and 24 h; watch for rebound
- refractory, anuric or on HD → nephrology/ICU for dialysis
K⁺ ≥6.5 or ECG changes (peaked T, wide QRS, loss of P, brady or VT). On haemodialysis → urgent dialysis as well.
- ECG changes → calcium gluconate 10% 30 mL IV over 10 min (chloride if peri-arrest); repeat if changes persist
- insulin 10 units soluble + glucose 25 g IV
- salbutamol 10–20 mg nebulised as an adjunct
- SZC 10 g TDS; refractory, oliguric AKI or ESKD → dialysis
- salbutamol on its own; routine IV bicarbonate
hyperkalaemia — acute treatment
| step | what | key details |
|---|---|---|
| 1. protect the heart | IV calcium (6.8 mmol) | gluconate 10% 30 mL over 10 min (all except arrest); chloride 10% 10 mL over 5 min (resuscitation). Only if ECG changes. Lasts 30–60 min |
| 2. shift K⁺ | insulin-glucose | 10 units soluble insulin + 25 g glucose IV for K⁺ ≥6.5 (1B), consider at 6.0–6.4 (2C) |
| salbutamol | 10–20 mg nebulised; adjunct only (1A against monotherapy) | |
| IV bicarbonate | not routine (2C) | |
| 3. remove K⁺ | SZC | 10 g TDS up to 72 h for ≥6.5 (1B); consider at 6.0–6.4. Onset about 1 h |
| patiromer | 8.4 g daily (≥6.0; 1C). Onset 4–7 h | |
| SPS / calcium resonium | no longer routine acutely (2B); colonic necrosis risk | |
| dialysis | refractory, oliguric AKI, ESKD | |
| 4. monitor | K⁺ and glucose | K⁺ at 1, 2, 4, 6, 24 h. Glucose for 6 h after insulin |
| 5. prevent | review cause | drugs, AKI, diet, constipation, acidosis, diabetes control |
- Insulin dose: UKKA keeps 10 units for everyone. 5 units lowers K⁺ less, and hypoglycaemia rates were similar (17.7% vs 18.7%). Prevent hypoglycaemia instead with the post-dose 10% glucose infusion when baseline glucose <7. Hypoglycaemia after 10 units + 25 g ≈ 25% in one series. Higher risk with CKD, low baseline glucose, repeated doses
- Calcium dose: 30 mL of 10% gluconate = 6.8 mmol (UKKA); 10 mL (1 g) is a third of that
- Digoxin toxicity: retrospective data don’t support the historic fear of IV calcium
- HD patients: urgent dialysis for K⁺ ≥6.5 (1A). IV calcium even if dialysis is available (1C). Binders between sessions (1B)
Insulin and glucose together. Salbutamol and IV bicarbonate are never monotherapy.
hyperkalaemia — chronic and outpatient
| K⁺ (mmol/L) | UKKA 2023 (community) |
|---|---|
| 5.5–5.9 | repeat within 3 days if unexpected (14 days if well, no AKI; unwell/AKI → consider referral); start K⁺-lowering measures; monitor more often; consider reducing RASi dose |
| 6.0–6.4 | repeat within 1 working day; refer to hospital if unwell or AKI |
| ≥6.5 | admit |
- Diabetes Canada 2025 uses different bands: mild ULN–5.4 (diet), moderate 5.5–5.9 (drugs to increase excretion), severe ≥6.0 (hold RASi/nsMRA, go to ED)
- Keep RASi where possible. KDIGO: treat the K⁺ (diet, diuretics, bicarbonate, binders) rather than stop the drug → potassium binders
- UKKA stops RASi at K⁺ ≥6.0 only if a binder isn’t an option
- stop RASi during acute illness (sepsis, hypovolaemia, AKI)
- Before starting: caution with ACEi/ARB if K⁺ >5.0 (1A). Avoid starting an MRA if K⁺ >5.0 or eGFR <30 (UKKA)
- U&E 1–2 weeks after starting or titrating ACEi/ARB. MRA: 1 week, then monthly × 3, then 3-monthly in year 1, then 4-monthly
- Persistent >5.5 in CKD → renal dietitian (after fixing constipation, acidosis, glycaemia)
- Oral bicarbonate if serum HCO₃⁻ <22 (UKKA). KDIGO 2024 uses <18 as its acidosis threshold
- Loop diuretic if non-oliguric and volume replete (2C)
- Trimethoprim: caution in CKD or with RASi
- RASi held for hyperkalaemia → retrial (possibly lower dose) once resolved; recheck if K⁺ rises >30% (Diabetes Canada)
- Monitor K⁺ 2–4×/year in CKD, HF or diabetes at risk; arrange community K⁺ after any admission treated for hyperkalaemia (UKKA)
- Hyperkalaemic cardiac arrest: IV calcium chloride (1C) + insulin 10 units/glucose 25 g (1B); bicarbonate suggested (2C)
causes to check
- Spurious: haemolysis, fist clenching, delayed processing, thrombocytosis/leucocytosis. Get an ECG and blood-gas K⁺ before calling a high result spurious
- Drugs: RASi, MRA, amiloride, trimethoprim, NSAIDs, CNIs, heparin, β-blockers, digoxin
- Reduced excretion: AKI/CKD, hyporeninaemic hypoaldosteronism (diabetes), adrenal insufficiency, obstruction
- Shift: acidosis, insulin deficiency/hyperglycaemia, cell lysis (TLS → tumour lysis syndrome, rhabdomyolysis)
hypokalaemia
work-up
- Exclude shift (insulin, β-agonists, alkalosis, refeeding, thyrotoxic/familial periodic paralysis)
- Urine K⁺ (spot K:Cr): low → GI loss or poor intake; high → renal loss
- Renal loss → BP and acid–base:
| BP | acid–base | think |
|---|---|---|
| high | alkalosis | primary aldosteronism (renin low, aldosterone high) → secondary hypertension; renovascular/renin-secreting (renin high); Cushing, liquorice, Liddle (both low) |
| normal/low | alkalosis | diuretics, vomiting (urine Cl⁻ low), Bartter, Gitelman |
| normal/low | acidosis | RTA type 1 or 2, DKA, amphotericin → acid-base disorders |
- Hypomagnesaemia drives renal K⁺ wasting → hypokalaemia won’t correct until Mg²⁺ is replaced → phosphate and magnesium disorders
- Endocrine Society 2025: unexplained or diuretic-induced hypokalaemia in hypertension → aldosterone/renin. Correct K⁺ first (low K⁺ lowers aldosterone → false-negative screen)
replacement
- Mild (3.0–3.4): oral KCl 40–80 mmol/day
- Moderate (2.5–2.9): oral KCl 80–120 mmol/day; IV if symptomatic or nil by mouth
- Severe (<2.5) or ECG changes: IV KCl ≤10–20 mmol/h peripherally, up to 40 mmol/h centrally with monitoring
- DKA: K⁺ <3.3 → hold insulin, replace first → diabetic ketoacidosis — management
- ECG: flat/inverted T, ST depression, U waves, long QT → torsades
inherited tubulopathies
| Bartter | Gitelman | Liddle | |
|---|---|---|---|
| site (mimics) | TAL (loop diuretic) | DCT NCC (thiazide) | collecting duct ENaC gain of function |
| inheritance | AR | AR | AD |
| K⁺ / pH | low / alkalosis | low / alkalosis | low / alkalosis |
| BP | normal–low | normal–low | high |
| renin/aldosterone | high/high | high/high | low/low |
| Mg²⁺ | normal or low | low | normal |
| urine Ca²⁺ | high (nephrocalcinosis) | low | normal |
| serum Ca²⁺ | normal | normal | normal |
| treatment | K⁺/Mg²⁺, NSAID, MRA/amiloride | K⁺/Mg²⁺, MRA/amiloride | amiloride or triamterene (spironolactone ineffective) |
Urine calcium separates them: high in Bartter (loop-like), low in Gitelman (thiazide-like). Serum calcium is normal in both.
Prepared 2026-10-30. Not yet verified — check every number against the sources.
Key references
- guidelineAlfonzo A, et al. UK Kidney Association Clinical Practice Guideline: Treatment of Acute Hyperkalaemia in Adults. October 2023.